enzalutamide,talazoparib
astellas,pfizer
['prostate']
excellent discussion by on #parp inhibitors in #prostatecancer #asco23 oral session. 
Clinical researcher focused on #ProstateCancer, early recurrence (#BCR)  & #immunotherapy. Views are my own & do not represent the National Cancer Institute